A cross species study of heterogeneity in fear extinction learning in relation to FKBP5 variation and expression: Implications for the acute treatment of posttraumatic stress disorder

Neuropharmacology

Volumn 116, Issue , 2017, Pages 188-195

  Galatzer Levy, Isaac R ^a,h   Andero, Raül ^b,f,g   Sawamura, Takehito ^c   Jovanovic, Tanja ^d,e   Papini, Santiago ⁱ   Ressler, Kerry J ^f,g   Norrholm, Seth Davin ^d,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Maritime Self Defense Force   (Japan)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

^f MCLEAN HOSPITAL   (United States)

^g HARVARD UNIVERSITY   (United States)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Dexamethasone; Fear extinction; FKBP5; Latent growth mixture modeling; mRNA; Posttraumatic stress; Resilience; Threat extinction; Translational model

Indexed keywords

DEXAMETHASONE; MESSENGER RNA; FK 506 BINDING PROTEIN; GLUCOCORTICOID; TACROLIMUS BINDING PROTEIN 5;

ADULT; AMYGDALA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS SPECIES STUDY; DISEASE ASSOCIATION; FEAR; FEAR EXTINCTION LEARNING; FEMALE; FKBP5 GENE; GENE EXPRESSION; GENOTYPE; HOMOZYGOTE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RECALL; SINGLE NUCLEOTIDE POLYMORPHISM; STUDY DESIGN; ANIMAL; AROUSAL; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; REINFORCEMENT; STARTLE REFLEX;

ADULT; AMYGDALA; ANIMALS; AROUSAL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MENTAL RECALL; MICE; POLYMORPHISM, SINGLE NUCLEOTIDE; REFLEX, STARTLE; RNA, MESSENGER; STRESS DISORDERS, POST-TRAUMATIC; TACROLIMUS BINDING PROTEINS;

EID: 85008394115     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.12.023     Document Type: Article

References (35)

1. Binder, E.B., The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34 (2009), S186–S195.
2. Binder, E.B., Salyakina, D., Lichtner, P., Wochnik, G.M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M.A., Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 (2004), 1319–1325.
3. Blake, D.D., Weathers, F.W., Nagy, L.M., Kaloupek, D.G., Gusman, F.D., Charney, D.S., Keane, T.M., The development of a clinician-administered PTSD scale. J. Trauma. Stress 8 (1995), 75–90.
4. Cole, M.A., Kim, P.J., Kalman, B.A., Spencer, R.L., Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology 25 (2000), 151–167.
5. de Kloet, C.S., Vermetten, E., Geuze, E., Lentjes, E.G., Heijnen, C.J., Stalla, G.K., Westenberg, H.G., Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. Prog. Brain Res. 167 (2008), 287–291.
6. Fani, N., King, T.Z., Brewster, R., Srivastava, A., Stevens, J.S., Glover, E.M., Norrholm, S.D., Bradley, B., Ressler, K.J., Jovanovic, T., Fear-potentiated startle during extinction is associated with white matter microstructure and functional connectivity. Cortex 64 (2015), 249–259.
7. Fani, N., Tone, E.B., Phifer, J., Norrholm, S.D., Bradley, B., Ressler, K.J., Kamkwalala, A., Jovanovic, T., Attention bias toward threat is associated with exaggerated fear expression and impaired extinction in PTSD. Psychol. Med. 42 (2012), 533–543.
8. Galatzer-Levy, I., Empirical characterization of heterogeneous posttraumatic stress responses is necessary to improve the science of posttraumatic stress. J. Clin. Psychiatry, 75, 2014, e950.
9. Galatzer-Levy, I.R., Ankri, Y., Freedman, S., Israeli-Shalev, Y., Roitman, P., Gilad, M., Shalev, A.Y., Early PTSD symptom trajectories: persistence, recovery, and response to treatment: results from the jerusalem trauma outreach and prevention study (J-TOPS). PLoS One, 8, 2013, e70084.
10. Galatzer-Levy, I.R., Bonanno, G.A., Bush, D.E., LeDoux, J.E., Heterogeneity in threat extinction learning: substantive and methodological considerations for identifying individual difference in response to stress. Front. Behav. Neurosci., 7, 2013.
11. Holt, D.J., Lebron-Milad, K., Milad, M.R., Rauch, S.L., Pitman, R.K., Orr, S.P., Cassidy, B.S., Walsh, J.P., Goff, D.C., Extinction memory is impaired in schizophrenia. Biol. Psychiatry 65 (2009), 455–463.
12. Jovanovic, T., Kazama, A., Bachevalier, J., Davis, M., Impaired safety signal learning may be a biomarker of PTSD. Neuropharmacology 62 (2012), 695–704.
13. Jovanovic, T., Norrholm, S.D., Blanding, N.Q., Davis, M., Duncan, E., Bradley, B., Ressler, K.J., Impaired fear inhibition is a biomarker of PTSD but not depression. Depress. anxiety 27 (2010), 244–251.
14. Jovanovic, T., Norrholm, S.D., Blanding, N.Q., Phifer, J.E., Weiss, T., Davis, M., Duncan, E., Bradley, B., Ressler, K., Fear potentiation is associated with hypothalamic–pituitary–adrenal axis function in PTSD. Psychoneuroendocrinology 35 (2010), 846–857.
15. Jovanovic, T., Norrholm, S.D., Fennell, J.E., Keyes, M., Fiallos, A.M., Myers, K.M., Davis, M., Duncan, E.J., Posttraumatic stress disorder may be associated with impaired fear inhibition: relation to symptom severity. Psychiatry Res. 167 (2009), 151–160.
16. Jovanovic, T., Norrholm, S.D., Keyes, M., Fiallos, A., Jovanovic, S., Myers, K.M., Davis, M., Duncan, E.J., Contingency awareness and fear inhibition in a human fear-potentiated startle paradigm. Behav. Neurosci., 120, 2006, 995.
17. Jovanovic, T., Phifer, J.E., Sicking, K., Weiss, T., Norrholm, S.D., Bradley, B., Ressler, K.J., Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology 36 (2011), 1540–1552.
18. Kilpatrick, D.G., Resnick, H.S., Milanak, M.E., Miller, M.W., Keyes, K.M., Friedman, M.J., National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J. Trauma. stress 26 (2013), 537–547.
19. LeDoux, J., Rethinking the emotional brain. Neuron 73 (2012), 653–676.
20. Mehta, D., Binder, E.B., Gene× environment vulnerability factors for PTSD: the HPA-axis. Neuropharmacology 62 (2012), 654–662.
21. Meijer, O., De Lange, E., Breimer, D., De Boer, A., Workel, J., De Kloet, E., Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-Glycoprotein knockout mice 1. Endocrinology 139 (1998), 1789–1793.
22. Milad, M.R., Pitman, R.K., Ellis, C.B., Gold, A.L., Shin, L.M., Lasko, N.B., Zeidan, M.A., Handwerger, K., Orr, S.P., Rauch, S.L., Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol. Psychiatry 66 (2009), 1075–1082.
23. Milad, M.R., Rauch, S.L., Pitman, R.K., Quirk, G.J., Fear extinction in rats: implications for human brain imaging and anxiety disorders. Biol. Psychol. 73 (2006), 61–71.
24. Miller, A.H., Spencer, R.L., Pulera, M., Kang, S., McEwen, B.S., Stein, M., Adrenal steroid receptor activation in rat brain and pituitary following dexamethasone: implications for the dexamethasone suppression test. Biol. Psychiatry 32 (1992), 850–869.
25. Norrholm, S.D., Glover, E.M., Stevens, J.S., Fani, N., Galatzer-Levy, I.R., Bradley, B., Ressler, K.J., Jovanovic, T., Fear load: the psychophysiological over-expression of fear as an intermediate phenotype associated with trauma reactions. Int. J. Psychophysiol. 98:2 (November 2015), 270–275 Part 2.
26. Norrholm, S.D., Jovanovic, T., Olin, I.W., Sands, L.A., Bradley, B., Ressler, K.J., Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol. psychiatry 69 (2011), 556–563.
27. Norrholm, S.D., Jovanovic, T., Vervliet, B., Myers, K.M., Davis, M., Rothbaum, B.O., Duncan, E.J., Conditioned fear extinction and reinstatement in a human fear-potentiated startle paradigm. Learn. Mem. 13 (2006), 681–685.
28. Quirk, G.J., Mueller, D., Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 33 (2008), 56–72.
29. Ressler, K.J., Mayberg, H.S., Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat. Neurosci. 10 (2007), 1116–1124.
30. Sawamura, T., Klengel, T., Armario, A., Jovanovic, T., Norrholm, S.D., Ressler, K.J., Andero, R., Dexamethasone treatment leads to enhanced fear extinction and dynamic Fkbp5 regulation in amygdala. Neuropsychopharmacology 41:3 (2016), 832–846.
31. Simeon, D., Knutelska, M., Yehuda, R., Putnam, F., Schmeidler, J., Smith, L.M., Hypothalamic-pituitary-adrenal axis function in dissociative disorders, post-traumatic stress disorder, and healthy volunteers. Biol. Psychiatry 61 (2007), 966–973.
32. Yang, Y.-L., Chao, P.-K., Lu, K.-T., Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 31 (2006), 912–924.
33. Yang, Y.-L., Chao, P.-K., Ro, L.-S., Wo, Y.-Y.P., Lu, K.-T., Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology 32 (2007), 1042–1051.
34. Yehuda, R., Status of glucocorticoid alterations in post-traumatic stress disorder. Ann. N. Y. Acad. Sci. 1179 (2009), 56–69.
35. Yehuda, R., Flory, J.D., Pratchett, L.C., Buxbaum, J., Ising, M., Holsboer, F., Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD. Psychopharmacol. Berl. 212:3 (2010), 405–417.